TONG Chu-hong,BAI Jie,LIU Jing,et al.Acoustic Injury Induced by Platinum in Children with Solid Tumors[J].Chinese Scientific Journal of Hearing and Speech Rehabilitation,2025,23(02):140-144.
TONG Chu-hong,BAI Jie,LIU Jing,et al.Acoustic Injury Induced by Platinum in Children with Solid Tumors[J].Chinese Scientific Journal of Hearing and Speech Rehabilitation,2025,23(02):140-144.DOI: 10.3969/j.issn.1672-4933.2025.02.008.
Acoustic Injury Induced by Platinum in Children with Solid Tumors
To explore the relationship between cisplatin and carboplatin and hearing loss caused by platinum drugs in solid tumors in children.
Methods
2
From January 2020 to December 2023
children with solid tumors who used carboplatin and/or cisplatin in the Department of Medical Oncology
Beijing Children's Hospital
Capital Medical University
were enrolled for hearing monitoring and statistical analysis using R language.
Results
2
622 children were included in this study
of which 72 (11.6%) developed hearing loss
and the median time of hearing loss was 12 months (1-124 months) after the initiation of platinum drugs. Multivariate analysis showed that cisplatin
cisplatin combined with carboplatin
cranial radiotherapy
and cisplatin with furosemide were associated with hearing loss (
P
<
0.05). There was a nonlinear relationship between the cumulative cisplatin dose and hearing loss
with a 50% increase in the risk of hearing loss for every 100 mg/m
2
increase in cisplatin when the cumulative cisplatin dose was greater than 680 mg/m
2
. The relationship between carboplatin and hearing loss was uncertain (
P
>
0.05).
Conclusion
2
Cisplatin is associated with the risk of hearing loss in children with solid tumors. When the cumulative dose of cisplatin exceeds 680 mg/m2
the risk of hearing loss is significantly increased.
关键词
Keywords
references
Oun R , Moussa YE , Wheate NJ . The side effects of platinum-based chemotherapy drugs: a review for chemists [J ] . Dalton Trans , 2018 , 47 ( 19 ): 6645 - 6653 .
Strebel S , Baust K , Grabow D , et al . Auditory complications among childhood cancer survivors and health-related quality of life: a PanCareLIFE study [J ] . J Cancer Surviv , 2025 , 19 ( 1 ): 162 - 173 .
Li Y , Womer RB , Silber JH . Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose [J ] . Eur J Cancer , 2004 , 40 ( 16 ): 2445 - 2451 .
Neuwelt EA , Brummett RE , Doolittle ND , et al . First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate [J ] . J Pharmacol Exp Ther , 1998 , 286 ( 1 ): 77 - 84 .
Landier W , Knight K , Wong FL , et al . Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group [J ] . J Clin Oncol , 2014 , 32 ( 6 ): 527 - 534 .
Clemens E , De Vries AC , Pluijm SF , et al . Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study [J ] . Eur J Cancer , 2016 , 69 : 77 - 85 .
Moke DJ , Luo C , Millstein J , et al . Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study [J ] . Lancet Child Adolesc Health , 2021 , 5 ( 4 ): 274 - 283 .
Schell MJ , McHaney VA , Green AA , et al . Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation [J ] . J Clin Oncol , 1989 , 7 ( 6 ): 754 - 760 .
Keilty D , Khandwala M , Liu ZA , et al . Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children [J ] . J Clin Oncol , 2021 , 39 ( 34 ): 3813 - 3821 .
Huitema AD , Spaander M , Mathjt RA , et al . Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin [J ] . Ann Oncol , 2002 , 13 ( 3 ): 374 - 384 .
Friedman DL , Himelstein B , Shields CL , et al . Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma [J ] . J Clin Oncol , 2000 , 18 ( 1 ): 12 - 17 .
Martinez JA , Martin G , Sanz GF , et al . A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia [J ] . J Clin Oncol , 1991 , 9 ( 1 ): 39 - 43 .
Brock PR , Knight KR , Freyer DR , et al . Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale [J ] . J Clin Oncol , 2012 , 30 ( 19 ): 2408 - 2417 .
Clemens E , Van den Heuvel-Eibrink MM , Mulder RL , et al . Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium [J ] . Lancet Oncol , 2019 , 20 ( 1 ): e29 - e41 .
Beyea JA , Lau C , Cooke B , et al . Long-Term Incidence and Predictors of Significant Hearing Loss Requiring Hearing Assistive Devices Among Childhood Cancer Survivors: A Population-Based Study [J ] . J Clin Oncol , 2020 , 38 ( 23 ): 2639 - 2646 .
Funt SA , Knezevic A , Wilson K , et al . Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors [J ] . Cancer , 2023 , 129 ( 24 ): 3952 - 3961 .
Frisina RD , Wheeler HE , Fossa SD , et al . Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer [J ] . J Clin Oncol , 2016 , 34 ( 23 ): 2712 - 2720 .